The Company reports unaudited total revenue of US$114.9M1 (AU$175.0M) an increase of 18% on
the prior quarter (US$97.1M2 or AU$148.1M). Revenue was primarily generated from sales of Telix’s
prostate cancer imaging product Illuccix®.
U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth
between Q3 2023 and Q4 2023.
The Company reports unaudited total revenue of US$114.9M1...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.80 |
Change
0.130(0.89%) |
Mkt cap ! $4.890B | |||
| Open | High | Low | Value | Volume |
| $14.79 | $15.05 | $14.79 | $15.92M | 1.069M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3546 | $14.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.81 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$14.80 |
Change
0.130 ( 0.67 %) |
||||
| Open | High | Low | Volume | ||
| $14.72 | $15.05 | $14.72 | 222019 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| TLX (ASX) Chart |